Clinical Outcomes of Patients Receiving Fluoroquinolones to Treat Bacteremia Caused by Enterobacteriaceae Isolates Considered Intermediate or Resistant to These Agents According to the Recently Revised Susceptibility Testing Standards by the Clinical and Laboratory Standards Institute (CLSI)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.